Cellectis - Asset Resilience Ratio

Latest as of September 2025: 96.26%

Cellectis (ALCLS) has an Asset Resilience Ratio of 96.26% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ALCLS current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€330.20 Million

≈ $386.04 Million USD Cash + Short-term Investments

Total Assets

€343.05 Million

≈ $401.06 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2024)

This chart shows how Cellectis's Asset Resilience Ratio has changed over time. See ALCLS book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Cellectis's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cellectis (ALCLS) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€192.22 Million	56.03%
Short-term Investments	€137.98 Million	40.22%
Total Liquid Assets	€330.20 Million	96.26%

Asset Resilience Insights

Very High Liquidity: Cellectis maintains exceptional liquid asset reserves at 96.26% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Cellectis Industry Peers by Asset Resilience Ratio

Compare Cellectis's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Cellectis (2006–2024)

The table below shows the annual Asset Resilience Ratio data for Cellectis.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	59.29%	€227.39 Million ≈ $265.84 Million	€383.54 Million ≈ $448.40 Million	+22.76pp
2023-12-31	36.53%	€122.11 Million ≈ $142.76 Million	€334.27 Million ≈ $390.80 Million	+29.22pp
2022-12-31	7.31%	€19.11 Million ≈ $22.34 Million	€261.22 Million ≈ $305.39 Million	-5.36pp
2021-12-31	12.67%	€48.41 Million ≈ $56.60 Million	€382.08 Million ≈ $446.69 Million	-9.41pp
2020-12-31	22.08%	€103.65 Million ≈ $121.18 Million	€469.47 Million ≈ $548.86 Million	+2.77pp
2019-12-31	19.31%	€90.28 Million ≈ $105.54 Million	€467.47 Million ≈ $546.52 Million	+8.59pp
2018-12-31	10.72%	€53.71 Million ≈ $62.79 Million	€500.84 Million ≈ $585.53 Million	-21.20pp
2016-12-31	31.93%	€105.58 Million ≈ $123.43 Million	€330.68 Million ≈ $386.60 Million	+9.94pp
2007-12-31	21.99%	€11.85 Million ≈ $13.85 Million	€53.87 Million ≈ $62.98 Million	+19.41pp
2006-12-31	2.58%	€287.00K ≈ $335.53K	€11.13 Million ≈ $13.01 Million	--

pp = percentage points

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$282.27 Million

€241.44 Million EUR

Market Cap Rank

#15207 Global

#222 in France

Share Price

€3.33

Change (1 day)

+3.29%

52-Week Range

€1.23 - €4.57

All Time High

€40.90